Bronchodilatory effect of Zingiber officinale Roscoe (ginger) in guinea pigs
Purpose: To determine the bronchodilatory effect of ginger on histamine-induced bronchospasm in guinea pigs.
Methods: Thirty-six guinea pigs weighing 400 - 700 g were randomly divided into six groups. Group 1 received distilled water, while group 2 was given formoterol (1.55 μg/kg) + budesonide (0.02 mg/kg). Guinea pigs in groups 3 and 4 were given ginger (350 and 700 mg/kg, respectively), while those in groups 5 and 6 received ginger (350 and 700 mg/kg, respectively) in addition to formoterol (1.55 μg/kg) and budesonide (0.02 mg/kg). Pre-convulsion time and percent protection in each group was calculated.
Results: There was statistically significant improvement in pre-convulsion times, with values of 156.64 ± 32.93, 299.33 ± 44.20, and 235.99 ± 34.55 s for groups 2, 5 and 6, respectively (p < 0.01). Moreover, statistically significant protection values of 73 and 68 % were obtained for groups 5 and 6, respectively, relative to normal control (p < 0.01).
Conclusion: These results indicate that ginger has promising potential for use as an add-on treatment for bronchospasm.
Keywords: Zingiber officinale, Histamine, Asthma, Pre-convulsion time
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.